Compare National Beverage Corp. (FIZZ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? National Beverage Corp. trades at $33.54 (market cap $3.08B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: National Beverage Corp. is far larger — about 3.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and National Beverage Corp. is more actively traded (604,078 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 32 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FIZZ | MRVI | |
|---|---|---|
Market Cap | $3.08B | $972.90M |
Volume | 604,078 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $9.00 |
52-Week Low | $29.20 | $2.83 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $3.04B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $33.54, up 4.32% with a bullish technical signal. The stock shows strong profitability with 14.81% net margins and 40.13% ROE, though recent quarters have seen earnings misses. Cash flow turned negative in 2025 due to significant financing outflows. Technical indicators suggest bullish momentum despite overbought RSI readings near 73.
FIZZ faces mixed sentiment with 50% analyst sell ratings but strong institutional interest. Revenue growth remains stagnant while margin pressure from input costs presents headwinds. The current valuation at 17.7x P/E appears reasonable given profitability, but execution risks and competitive pressures warrant caution for investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
